{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:11:37Z","timestamp":1773223897035,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.7759\/cureus.104983","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:08:58Z","timestamp":1773148138000},"source":"Crossref","is-referenced-by-count":0,"title":["Can P1NP Levels Influence Management Planning for Patients With a Fragility Hip Fracture Receiving Anti-resorptive Medications?"],"prefix":"10.7759","author":[{"given":"Mustafa","family":"Kraidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somaditya","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Osteoporosis. assessing the risk of fragility fracture. (2012). Accessed: July 2024: https:\/\/www.nice.org.uk\/guidance\/cg146."},{"key":"ref2","unstructured":"The National Hip Fracture Database annual report. (2017). Accessed. July 2024: https:\/\/www.nhfd.co.uk\/20\/hipfracturer.nsf\/vwContent\/NHFDNationalReport2017."},{"key":"ref3","unstructured":"Section 7. strategies for management of osteoporosis and fracture risk. Duration and monitoring of bisphosphonate treatment. (2021). Accessed: July 2024: https:\/\/www.nogg.org.uk\/full-guideline\/section-7-strategies-management-osteoporosis-and-fracture-risk."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell R","year":"2017","unstructured":"Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017, 5:908-23. 10.1016\/S2213-8587(17)30184-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9629891","article-title":"Changes in testing and treatment methods in osteoporosis care","volume":"2024","author":"Nagai T","year":"2024","unstructured":"Nagai T, Ishikawa K, Tsuchiya K, et al.. Changes in testing and treatment methods in osteoporosis care. J Osteoporos. 2024, 2024:9629891. 10.1155\/2024\/9629891","journal-title":"J Osteoporos"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.33176\/AACB-20-0001","article-title":"The role of PINP in diagnosis and management of metabolic bone disease","volume":"42","author":"Gillett MJ","year":"2021","unstructured":"Gillett MJ, Vasikaran SD, Inderjeeth CA. The role of PINP in diagnosis and management of metabolic bone disease. Clin Biochem Rev. 2021, 42:3-10. 10.33176\/AACB-20-0001","journal-title":"Clin Biochem Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2012.32.2.105","article-title":"Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis","volume":"32","author":"Lee J","year":"2012","unstructured":"Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 2012, 32:105-12. 10.3343\/alm.2012.32.2.105","journal-title":"Ann Lab Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116347","article-title":"Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation)","volume":"158","author":"Mattia L","year":"2022","unstructured":"Mattia L, Davis S, Mark-Wagstaff C, Abrahamsen B, Peel N, Eastell R, Schini M. Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation). Bone. 2022, 158:116347. 10.1016\/j.bone.2022.116347","journal-title":"Bone"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran S","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O, et al.. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011, 22:391-420. 10.1007\/s00198-010-1501-1","journal-title":"Osteoporos Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-016-0278-z","article-title":"A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis JA","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, McCloskey EV. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016, 11:25. 10.1007\/s11657-016-0278-z","journal-title":"Arch Osteoporos"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy214.06","article-title":"Can P1NP levels aid decision making in patients who sustain a hip fracture whilst on bisphosphonate treatment?","volume":"48","author":"Wilkinson I","year":"2019","unstructured":"Wilkinson I, Griffiths S, Bandyopadhyay S, et al.. Can P1NP levels aid decision making in patients who sustain a hip fracture whilst on bisphosphonate treatment?. Age Ageing. 2019, 48:17-8. 10.1093\/ageing\/afy214.06","journal-title":"Age Ageing"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.44.2.126","article-title":"The use of bone-turnover markers in Asia-Pacific populations","volume":"44","author":"Vasikaran S","year":"2024","unstructured":"Vasikaran S, Thambiah SC, Tan RZ, et al.. The use of bone-turnover markers in Asia-Pacific populations. Ann Lab Med. 2024, 44:126-34. 10.3343\/alm.2024.44.2.126","journal-title":"Ann Lab Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102399","article-title":"Intra-individual changes in total procollagen-type 1 N-terminal propeptide in a Korean adult population","volume":"12","author":"Choi R","year":"2022","unstructured":"Choi R, Lee SG, Lee EH. Intra-individual changes in total procollagen-type 1 N-terminal propeptide in a Korean adult population. Diagnostics (Basel). 2022, 12:2399. 10.3390\/diagnostics12102399","journal-title":"Diagnostics (Basel)"},{"key":"ref14","unstructured":"P1NP-biochemistry test information. (2023). Accessed. December 2025: https:\/\/pathology.uhsussex.nhs.uk\/pug\/biochemistry-immunology\/biochemistry-tests\/507-p1np."},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez A","year":"2017","unstructured":"Diez-Perez A, Naylor KE, Abrahamsen B, et al.. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017, 28:767-74.","journal-title":"Osteoporos Int"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-017-0272-1","article-title":"The utility of biomarkers in osteoporosis management","volume":"21","author":"Garnero P","year":"2017","unstructured":"Garnero P. The utility of biomarkers in osteoporosis management. Mol Diagn Ther. 2017, 21:401-18.","journal-title":"Mol Diagn Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung MR","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, et al.. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014, 370:412-20. 10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447709-can-p1np-levels-influence-management-planning-for-patients-with-a-fragility-hip-fracture-receiving-anti-resorptive-medications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:08:59Z","timestamp":1773148139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447709-can-p1np-levels-influence-management-planning-for-patients-with-a-fragility-hip-fracture-receiving-anti-resorptive-medications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.104983","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}